MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

27.65 +0.55 (+2.03%)
Official Closing Price Updated: 7:00 PM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
News headline image
PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
From Pfizer Inc.
Via Business Wire
News headline image
U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer
From Pfizer Inc.
Via Business Wire
TinyGemsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Dr. Freda Lewis-Hall to Board and Scientific Advisory Committee Chair
Via Investor Brand Network
News headline image
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio This news release... 
Via FinancialNewsMedia
News headline image
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
From Pfizer Inc.
Via Business Wire
News headline image
FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans
From Pfizer Inc.
Via Business Wire
News headline image
Men's Health Network Launches "My Cancer, My Plan" Podcast on World Cancer Day
Via PRLog
Topics Death
News headline image
Rigani Press Announces BioCT's Inaugural Book Event Featuring Dr. S. Yin Ho
Via PRLog
Topics Artificial Intelligence
News headline image
Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial
From Pfizer Inc.
Via Business Wire
News headline image
Cayenne Wellness Center Celebrates 25 Years of Impact With Star-Studded Fundraising Gala
January 22, 2026 -- Supporting Sickle Cell Wellness 
Via 24-7 Press Release
News headline image
Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer
From Pfizer Inc.
Via Business Wire
News headline image
Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio
From Levin Papantonio
Via Business Wire
News headline image
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance
From Pfizer Inc.
Via Business Wire
News headline image
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Rigani Press Announces Barnes & Noble Book Signing for Dr. S. Yin Ho's Groundbreaking Book
Via PRLog
Topics Artificial Intelligence
News headline image
Pfizer Declares First-Quarter 2026 Dividend
From Pfizer Inc.
Via Business Wire
News headline image
TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma
From Pfizer Inc.
Via Business Wire
News headline image
Government Relations and Policy Professional Kimberly Pinter Joins Bracewell's Policy Resolution Group in Washington, DC
Washington, D.C.--(Newsfile Corp. - December 8, 2025) - Bracewell LLP announced today that Kimberly J. Pinter has joined the firm's... 
Via Newsfile
News headline image
HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors
From Pfizer Inc.
Via Business Wire
News headline image
A Tale Told Through a Bird’s Eyes: Jessica Mann’s Uplift Reimagines How We See the Natural World
Via AB Newswire
Topics Bonds
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
Via Investor Brand Network
Topics Government
News headline image
Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance
From Pfizer Inc.
Via Business Wire
News headline image
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
From BioMedWire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story